CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has
CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc.
NEW YORK--(BUSINESS WIRE)-- Fourth graph, first sentence of release should read: If you purchased the common stock of Spectrum from August 8, 2012 through March 12, 2013 (the "Class") and you wish to serve as lead plaintiff in this action, you must move the Court no later than May 13, 2013. (sted May 16, 2013).
The corrected release reads:
ABRAHAM, FRUCHTER & TWERSKY, LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST SPECTRUM PHARMACEUTICALS, INC.
Abraham, Fruchter & Twersky, LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of all persons or entities who purchased the common stock of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (NAS: SPPI) from August 8, 2012 through March 12, 2013, inclusive (the "Class Period"). The complaint alleges violations of Section 10(b) of the Securities and Exchange Act of 1934 and Rule 10b-5, promulgated thereunder, against the Company and certain of its officers and directors.
The complaint alleges that throughout the Class Period, defendants made false and misleading statements to the investing public by dismissing concerns that sales of FUSILEV® (an oncology drug manufactured by Spectrum) would be adversely affected by increased supplies of leucovorin (a generic and competing drug of FUSILEV) and concealing the impact that the increased availability of leucovorin would have on FUSILEV sales. The complaint alleges that the defendants knew that when the availability of leucovorin increased, Spectrum would not be able to sustain its business outlook and revenue projections.
After the market closed on March 12, 2013, Spectrum surprised the market by reporting in a press release that sales of FUSILEV would be dropping significantly due to "a change in ordering patterns of FUSILEV." The Company also decreased their full-year 2013 revenues forecast to a range of $160 to $180 million, significantly lower than analysts' revenue expectations of $297.33 million. In a reaction to this news, shares of Spectrum common stock fell $4.64 per share, or 37%, on extremely high trading volume of 22.5 million shares.
If you purchased the common stock of Spectrum from August 8, 2012 through March 12, 2013 (the "Class") and you wish to serve as lead plaintiff in this action, you must move the Court no later than May 13, 2013. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed class.
If you would like to discuss this action or if you have any questions concerning this notice or your rights as a potential class member or lead plaintiff, you may contact: Arthur J. Chen of Abraham, Fruchter & Twersky, LLP toll free at (800) 440-8986, or via e-mail at email@example.com or firstname.lastname@example.org.
Abraham, Fruchter & Twersky, LLP has extensive experience in securities class action cases, and the firm has been ranked among the leading class action law firms in terms of recoveries achieved in a survey of class action law firms conducted by Institutional Shareholder Services.
|Arthur J. Chen|
|Abraham, Fruchter & Twersky, LLP|
|One Penn Plaza, Suite 2805|
|New York, N.Y. 10119|
|Telephone: (800) 440-8986|
|Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.|
KEYWORDS: United States North America New York
The article CORRECTING and REPLACING Abraham, Fruchter & Twersky, LLP Announces That a Class Action Lawsuit Has Been Filed against Spectrum Pharmaceuticals, Inc. originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.